Proficio Capital Partners LLC Purchases Shares of 46,089 MiMedx Group, Inc. (NASDAQ:MDXG)

Proficio Capital Partners LLC acquired a new stake in shares of MiMedx Group, Inc. (NASDAQ:MDXG) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 46,089 shares of the company’s stock, valued at approximately $443,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Disciplined Growth Investors Inc. MN lifted its position in shares of MiMedx Group by 0.8% in the third quarter. Disciplined Growth Investors Inc. MN now owns 355,387 shares of the company’s stock worth $2,100,000 after buying an additional 2,737 shares in the last quarter. SkyView Investment Advisors LLC grew its holdings in MiMedx Group by 30.0% during the 3rd quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the company’s stock valued at $77,000 after buying an additional 3,000 shares in the last quarter. Principal Financial Group Inc. increased its stake in MiMedx Group by 6.3% in the 3rd quarter. Principal Financial Group Inc. now owns 55,495 shares of the company’s stock worth $328,000 after acquiring an additional 3,292 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in shares of MiMedx Group by 0.7% during the 4th quarter. Bank of New York Mellon Corp now owns 504,007 shares of the company’s stock worth $4,849,000 after acquiring an additional 3,300 shares in the last quarter. Finally, Orion Capital Management LLC boosted its position in shares of MiMedx Group by 46.3% during the 3rd quarter. Orion Capital Management LLC now owns 11,700 shares of the company’s stock valued at $69,000 after acquiring an additional 3,700 shares during the last quarter. Institutional investors own 79.15% of the company’s stock.

MiMedx Group Stock Up 2.0 %

Shares of NASDAQ:MDXG opened at $8.10 on Tuesday. The company has a 50-day moving average price of $8.36 and a 200 day moving average price of $7.88. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10. MiMedx Group, Inc. has a 12 month low of $5.47 and a 12 month high of $10.14. The company has a market cap of $1.19 billion, a price-to-earnings ratio of 14.73 and a beta of 1.97.

MiMedx Group (NASDAQ:MDXG) last announced its earnings results on Wednesday, February 26th. The company reported $0.07 EPS for the quarter, hitting analysts’ consensus estimates of $0.07. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. The firm had revenue of $92.91 million during the quarter, compared to analysts’ expectations of $89.42 million. As a group, equities research analysts predict that MiMedx Group, Inc. will post 0.3 earnings per share for the current year.

Insiders Place Their Bets

In other MiMedx Group news, insider Kimberly Maersk-Moller sold 4,106 shares of the firm’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $7.89, for a total value of $32,396.34. Following the completion of the sale, the insider now owns 310,836 shares of the company’s stock, valued at $2,452,496.04. This trade represents a 1.30 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO William Frank Iv Hulse sold 81,446 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $7.80, for a total value of $635,278.80. Following the transaction, the chief accounting officer now owns 494,774 shares of the company’s stock, valued at $3,859,237.20. This trade represents a 14.13 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 144,018 shares of company stock valued at $1,130,312 over the last three months. 1.30% of the stock is owned by company insiders.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald restated an “overweight” rating and issued a $13.00 price target on shares of MiMedx Group in a research report on Thursday, February 27th.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.